thalidomide has been researched along with Cancer of Mouth in 11 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was originally marked as a sedative and anti-emetic, but was withdrawn after severe teratogenic effects had been discovered." | 6.49 | Thalidomide: features and potential significance in oral precancerous conditions and oral cancer. ( Chen, Q; He, M; Huang, H; Jin, X; Lu, S; Mu, D; Wang, L; Xing, X; Zeng, X, 2013) |
| "Thalidomide was originally marked as a sedative and anti-emetic, but was withdrawn after severe teratogenic effects had been discovered." | 2.49 | Thalidomide: features and potential significance in oral precancerous conditions and oral cancer. ( Chen, Q; He, M; Huang, H; Jin, X; Lu, S; Mu, D; Wang, L; Xing, X; Zeng, X, 2013) |
| "Thalidomide has been shown to have anti-angiogenic effects in pre-clinical models as well as a significant antitumor effect in hematologic tumors." | 1.35 | Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis. ( Ge, JP; Yang, Y; Zhou, ZT, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, X | 1 |
| Wu, L | 1 |
| Shi, X | 1 |
| He, X | 1 |
| Li, W | 1 |
| Zhou, H | 1 |
| de Assis Pereira Hansen, C | 1 |
| Filho, JS | 1 |
| de Mattos Nascimento, M | 1 |
| Alves, FA | 1 |
| Neotti, T | 1 |
| D Almeida Costa, F | 1 |
| Molinari, AJ | 3 |
| Thorp, SI | 2 |
| Portu, AM | 1 |
| Saint Martin, G | 1 |
| Pozzi, EC | 3 |
| Heber, EM | 3 |
| Bortolussi, S | 1 |
| Itoiz, ME | 3 |
| Aromando, RF | 3 |
| Monti Hughes, A | 3 |
| Garabalino, MA | 3 |
| Altieri, S | 1 |
| Trivillin, VA | 3 |
| Schwint, AE | 3 |
| Yang, Y | 2 |
| Ge, JP | 2 |
| Zhou, ZT | 1 |
| Zhu, YQ | 1 |
| Jiang, L | 1 |
| Li, LF | 1 |
| Miller, M | 1 |
| Nigg, DW | 2 |
| Jin, X | 1 |
| Lu, S | 1 |
| Xing, X | 1 |
| Wang, L | 1 |
| Mu, D | 1 |
| He, M | 1 |
| Huang, H | 1 |
| Zeng, X | 1 |
| Chen, Q | 1 |
| Porter, SR | 1 |
| Jorge, J | 1 |
| Myoung, H | 1 |
| Hong, SD | 1 |
| Kim, YY | 1 |
| Hong, SP | 1 |
| Kim, MJ | 1 |
| Nadeau, J | 1 |
2 reviews available for thalidomide and Cancer of Mouth
| Article | Year |
|---|---|
Thalidomide: features and potential significance in oral precancerous conditions and oral cancer.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Feasibility Studies; Humans; Lichen Planus, Oral; Lu | 2013 |
Thalidomide: a role in oral oncology?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Mouth Neoplasms; N | 2002 |
9 other studies available for thalidomide and Cancer of Mouth
| Article | Year |
|---|---|
Extramammary Paget's disease of the oral mucosa and perioral skin.
Topics: Angiogenesis Inhibitors; Diagnosis, Differential; Female; Humans; Middle Aged; Mouth Neoplasms; Page | 2017 |
Extramedullary Manifestation of Multiple Myeloma in the Oral Cavity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Fata | 2018 |
Assessing advantages of sequential boron neutron capture therapy (BNCT) in an oral cancer model with normalized blood vessels.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Boron Compounds; Boron Neutron C | 2015 |
Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Carcino | 2009 |
Thalidomide induces apoptosis in human oral squamous cell carcinoma cell line with altered expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Topics: Apoptosis; Carcinoma, Squamous Cell; Humans; Immunosuppressive Agents; Mouth Neoplasms; Thalidomide; | 2011 |
Tumor blood vessel "normalization" improves the therapeutic efficacy of boron neutron capture therapy (BNCT) in experimental oral cancer.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Boron Compounds; Boron Neutron Capture Therapy; Che | 2012 |
Blood vessel normalization in the hamster oral cancer model for experimental cancer therapy studies.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Capillary Permeability; Case-Control Studies; Cheek | 2012 |
Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drug | 2001 |
Special prostheses.
Topics: Abnormalities, Drug-Induced; Athletic Injuries; Dentures; Facial Neoplasms; Humans; Lip; Mandibular | 1968 |